UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

SCHEDULE 13G/A

 

Under the Securities Exchange Act of 1934
(Amendment No. 4)*

 

APELLIS PHARMACEUTICALS, INC.

(Name of Issuer)

 

Common Stock, par value $0.0001 per share

(Title of Class of Securities)

 

03753U 106

(CUSIP Number)

 

December 31, 2020

(Date of Event Which Requires Filing of this Statement)

 

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

¨ Rule 13d-1(b)
¨ Rule 13d-1(c)
x Rule 13d-1(d)

 

*The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

 

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

 

 

 

 

 

CUSIP No. 03753U 106
 
  1. Names of Reporting Persons. I.R.S. Identification Nos. of above persons (entities only)
Morningside Venture Investments Ltd
 
  2. Check the Appropriate Box if a Member of a Group (See Instructions)
    (a) x
    (b) o
 
  3. SEC Use Only
 
  4. Citizenship or Place of Organization
British Virgin Islands
     
Number of
Shares
Beneficially
Owned by
Each
Reporting
Person With
5. Sole Voting Power
0
 
6. Shared Voting Power
12,556,342
 
7. Sole Dispositive Power
0
 
8. Shared Dispositive Power
12,556,342
 
  9. Aggregate Amount Beneficially Owned by Each Reporting Person
12,556,342
 
  10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)  o
 
  11. Percent of Class Represented by Amount in Row (9)
15.8% (1)
 
  12. Type of Reporting Person (See Instructions)
CO
           

 

(1) Based upon 75,736,924 shares of Common Stock outstanding as of October 28, 2020, as reported in the Issuer’s Form 10-Q filed with the Securities and Exchange Commission (the “SEC”) on November 2, 2020 and (ii) an additional 3,906,860 shares of Common Stock issued by the Issuer’s, as reported in the Issuer’s Current Report on Form 8-K filed with the SEC on January 26, 2021.

 

 

 

 

CUSIP No. 03753U 106
 
  1. Names of Reporting Persons. I.R.S. Identification Nos. of above persons (entities only)
Frances Anne Elizabeth Richard
 
  2. Check the Appropriate Box if a Member of a Group (See Instructions)
    (a) x
    (b) o
 
  3. SEC Use Only
 
  4. Citizenship or Place of Organization
United Kingdom
     
Number of
Shares
Beneficially
Owned by
Each
Reporting
Person With
5. Sole Voting Power
0
 
6. Shared Voting Power
12,556,342
 
7. Sole Dispositive Power
0
 
8. Shared Dispositive Power
12,556,342
 
  9. Aggregate Amount Beneficially Owned by Each Reporting Person
12,556,342
 
  10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)  o
 
  11. Percent of Class Represented by Amount in Row (9)
15.8% (1)
 
  12. Type of Reporting Person (See Instructions)
IN
           

 

(1) Based upon 75,736,924 shares of Common Stock outstanding as of October 28, 2020, as reported in the Issuer’s Form 10-Q filed with the SEC on November 2, 2020 and (ii) an additional 3,906,860 shares of Common Stock issued by the Issuer’s, as reported in the Issuer’s Current Report on Form 8-K filed with the SEC on January 26, 2021.

 

 

 

 

 CUSIP No. 03753U 106
 
  1. Names of Reporting Persons. I.R.S. Identification Nos. of above persons (entities only)
Cheung Ka Ho
 
  2. Check the Appropriate Box if a Member of a Group (See Instructions)
    (a) x
    (b) o
 
  3. SEC Use Only
 
  4. Citizenship or Place of Organization
Hong Kong
     
Number of
Shares
Beneficially
Owned by
Each
Reporting
Person With
5. Sole Voting Power
0
 
6. Shared Voting Power
12,556,342
 
7. Sole Dispositive Power
0
 
8. Shared Dispositive Power
12,556,342
 
  9. Aggregate Amount Beneficially Owned by Each Reporting Person
12,556,342
 
  10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)  o
 
  11. Percent of Class Represented by Amount in Row (9)
15.8% (1)
 
  12. Type of Reporting Person (See Instructions)
IN
           

 

(1) Based upon 75,736,924 shares of Common Stock outstanding as of October 28, 2020, as reported in the Issuer’s Form 10-Q filed with the SEC on November 2, 2020 and (ii) an additional 3,906,860 shares of Common Stock issued by the Issuer’s, as reported in the Issuer’s Current Report on Form 8-K filed with the SEC on January 26, 2021.

 

 

 

 

CUSIP No. 03753U 106
 
  1. Names of Reporting Persons. I.R.S. Identification Nos. of above persons (entities only)
Jill Marie Franklin
 
  2. Check the Appropriate Box if a Member of a Group (See Instructions)
    (a) x
    (b) o
 
  3. SEC Use Only
 
  4. Citizenship or Place of Organization
United Kingdom
     
Number of
Shares
Beneficially
Owned by
Each
Reporting
Person With
5. Sole Voting Power
0
 
6. Shared Voting Power
12,556,342
 
7. Sole Dispositive Power
0
 
8. Shared Dispositive Power
12,556,342
 
  9. Aggregate Amount Beneficially Owned by Each Reporting Person
12,556,342
 
  10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)  o
 
  11. Percent of Class Represented by Amount in Row (9)
15.8% (1)
 
  12. Type of Reporting Person (See Instructions)
IN
           

 

(1) Based upon 75,736,924 shares of Common Stock outstanding as of October 28, 2020, as reported in the Issuer’s Form 10-Q filed with the SEC on November 2, 2020 and (ii) an additional 3,906,860 shares of Common Stock issued by the Issuer’s, as reported in the Issuer’s Current Report on Form 8-K filed with the SEC on January 26, 2021.

 

 

 

 

CUSIP No. 03753U 106
 
  1. Names of Reporting Persons. I.R.S. Identification Nos. of above persons (entities only)
Peter Stuart Allenby Edwards
 
  2. Check the Appropriate Box if a Member of a Group (See Instructions)
    (a) x
    (b) o
 
  3. SEC Use Only
 
  4. Citizenship or Place of Organization
United Kingdom
     
Number of
Shares
Beneficially
Owned by
Each
Reporting
Person With
5. Sole Voting Power
0
 
6. Shared Voting Power
12,556,342
 
7. Sole Dispositive Power
0
 
8. Shared Dispositive Power
12,556,342
 
  9. Aggregate Amount Beneficially Owned by Each Reporting Person
12,556,342
 
  10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)  o
 
  11. Percent of Class Represented by Amount in Row (9)
15.8% (1)
 
  12. Type of Reporting Person (See Instructions)
IN
           

 

(1) Based upon 75,736,924 shares of Common Stock outstanding as of October 28, 2020, as reported in the Issuer’s Form 10-Q filed with the SEC on November 2, 2020 and (ii) an additional 3,906,860 shares of Common Stock issued by the Issuer’s, as reported in the Issuer’s Current Report on Form 8-K filed with the SEC on January 26, 2021.

 

 

 

 

Item 1.
  (a) Name of Issuer
Apellis Pharmaceuticals, Inc.
  (b) Address of Issuer’s Principal Executive Offices
100 Fifth Avenue
Waltham, MA 02451
 
Item 2.
  (a)

Name of Person Filing
Morningside Venture Investments Ltd

Frances Anne Elizabeth Richard

Cheung Ka Ho

Jill Marie Franklin

Peter Stuart Allenby Edwards

  (b)

Address of Principal Business Office or, if none, Residence
c/o THC Management Services S.A.M.

2nd Floor, Le Prince De Galles

3-5 Avenue Des Citronniers

MC 98000, Monaco

  (c)

Citizenship
Morningside Venture Investments Ltd – British Virgin Islands

Frances Anne Elizabeth Richard - United Kingdom

Cheung Ka Ho – Hong Kong

Jill Marie Franklin – United Kingdom

Peter Stuart Allenby Edwards – United Kingdom

  (d) Title of Class of Securities
Common Stock
  (e) CUSIP Number
03753U 106
 
Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
  (a) ¨ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).
  (b) ¨ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).
  (c) ¨ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).
  (d) ¨ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8).
  (e) ¨ An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
  (f) ¨ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
  (g) ¨ A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
  (h) ¨ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
  (i) ¨ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
  (j) ¨ Group, in accordance with §240.13d–1(b)(1)(ii)(J).

 

 

 

 

Item 4. Ownership
Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.
  (a)

Amount beneficially owned: (2)

 

Morningside Venture Investments Ltd – 12,556,342
Frances Anne Elizabeth Richard – 12,556,342
Cheung Ka Ho – 12,556,342
Jill Marie Franklin – 12,556,342
Peter Stuart Allenby Edwards – 12,556,342

 

  (b)

Percent of class:   

 

Morningside Venture Investments Ltd – 15.8%
Frances Anne Elizabeth Richard – 15.8%
Cheung Ka Ho – 15.8%
Jill Marie Franklin – 15.8%
Peter Stuart Allenby Edwards – 15.8%

 

  (c) Number of shares as to which the person has:
    (i)

Sole power to vote or to direct the vote   

 

Morningside Venture Investments Ltd – 0 shares
Frances Anne Elizabeth Richard – 0 shares
Cheung Ka Ho – 0 shares
Jill Marie Franklin – 0 shares
Peter Stuart Allenby Edwards – 0 shares

 

    (ii)

Shared power to vote or to direct the vote    

 

Morningside Venture Investments Ltd – 12,556,342 shares
Frances Anne Elizabeth Richard – 12,556,342 shares
Cheung Ka Ho – 12,556,342 shares
Jill Marie Franklin – 12,556,342 shares
Peter Stuart Allenby Edwards – 12,556,342 shares

 

    (iii)

Sole power to dispose or to direct the disposition of   

 

Morningside Venture Investments Ltd – 0 shares
Frances Anne Elizabeth Richard – 0 shares
Cheung Ka Ho – 0 shares
Jill Marie Franklin – 0 shares
Peter Stuart Allenby Edwards – 0 shares

 

 

 

 

 

    (iv)

Shared power to dispose or to direct the disposition of   

 

Morningside Venture Investments Ltd – 12,556,342shares
Frances Anne Elizabeth Richard – 12,556,342 shares
Cheung Ka Ho – 12,556,342 shares
Jill Marie Franklin – 12,556,342 shares
Peter Stuart Allenby Edwards – 12,556,342 shares

 

 

(2) This statement is filed by: (i) Morningside Venture Investments Ltd., a British Virgin Islands exempted company (“MVIL”), with respect to the Common Stock directly and beneficially owned by it; (ii) Frances Anne Elizabeth Richard, with respect to the Common Stock beneficially owned by her as a result of her position as a director with MVIL; (iii) Cheung Ka Ho, with respect to the Common Stock beneficially owned by him as a result of his position as a director with MVIL; (iv) Jill Marie Franklin, with respect to the Common Stock beneficially owned by her as a result of her position as a director of MVIL; and (v) Peter Stuart Allenby Edwards, with respect to the Common Stock beneficially owned by him as a result of his position as a director with MVIL.  Each of the foregoing is referred to as a “Reporting Person” and collectively as the “Reporting Persons.” 

 

Frances Anne Elizabeth Richard, Cheung Ka Ho, Jill Marie Franklin, and Peter Stuart Allenby Edwards are the directors of MVIL and share voting and dispositive power with respect to the securities held by MVIL.  Ms. Richard, Mr. Cheung, Ms. Franklin and Mr. Edwards each disclaims beneficial ownership of the securities owned directly by MVIL.  MVIL is ultimately wholly beneficially owned by a trust over which Adriel Wenbwo Chan and Wong Yuk Lan share authority to remove the trustee.

   
Item 5. Ownership of Five Percent or Less of a Class
If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following   ¨.
 
Item 6. Ownership of More than Five Percent on Behalf of Another Person
Not applicable.
 
Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person
Not applicable.
 
Item 8. Identification and Classification of Members of the Group
See attached for identification of Members of the Group.
 
Item 9. Notice of Dissolution of Group
Not applicable.

 

 

 

 

Item 10. Certification
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

 

Signature

 

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. We also hereby agree to file this statement jointly pursuant to the Agreement listed on Exhibit 99.1 hereto.

 

    February 11, 2021
    Date
     
     
    MORNINGSIDE VENTURE INVESTMENTS LTD.
     
     
  By: /s/ Frances Anne Elizabeth Richard
    Frances Anne Elizabeth Richard, Director
     
     
    /s/ Frances Anne Elizabeth Richard
    Frances Anne Elizabeth Richard
     
    /s/ Cheung Ka Ho
    Cheung Ka Ho
     
    /s/ Jill Marie Franklin
    Jill Marie Franklin
     
    /s/ Peter Stuart Allenby Edwards
    Peter Stuart Allenby Edwards

 

 

 

Apellis Pharmaceuticals (NASDAQ:APLS)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Apellis Pharmaceuticals Charts.
Apellis Pharmaceuticals (NASDAQ:APLS)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Apellis Pharmaceuticals Charts.